Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance 79% Improvement Relative Risk Viral clearance (b) 89% Viral clearance (c) 53% Viral clearance (d) 80% Viral clearance (e) 64% Viral clearance (f) 74% Arefin et al. NCT04549376 Povidone-Iodine RCT EARLY Does povidone-iodine reduce short-term viral load for COVID-19? RCT 189 patients in Bangladesh Improved viral clearance with povidone-iodine (p=0.018) Arefin et al., Indian J. Otolaryngology and Head.., doi:10.1007/s12070-021-02616-7 Favors povidone-iodine Favors control
Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial
Arefin et al., Indian Journal of Otolaryngology and Head & Neck Surgery, doi:10.1007/s12070-021-02616-7, NCT04549376 (history)
Arefin et al., Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial, Indian Journal of Otolaryngology and Head & Neck Surgery, doi:10.1007/s12070-021-02616-7, NCT04549376
May 2021   Source   PDF  
  All Studies   Meta
RCT with 189 patients showing significantly greater viral clearance with a single application of PVP-I. Authors recommend using PVP-I prophylactically in the nasopharynx and oropharynx. NCT04549376 (history) [].
risk of no viral clearance, 78.9% lower, RR 0.21, p = 0.02, treatment 4 of 27 (14.8%), control 19 of 27 (70.4%), NNT 1.8, 0.6% nasal irrigation.
risk of no viral clearance, 89.5% lower, RR 0.11, p < 0.001, treatment 2 of 27 (7.4%), control 19 of 27 (70.4%), NNT 1.6, 0.5% nasal irrigation.
risk of no viral clearance, 52.6% lower, RR 0.47, p = 0.006, treatment 9 of 27 (33.3%), control 19 of 27 (70.4%), NNT 2.7, 0.4% nasal irrigation.
risk of no viral clearance, 80.0% lower, RR 0.20, p < 0.001, treatment 5 of 27 (18.5%), control 25 of 27 (92.6%), NNT 1.4, 0.6% nasal spray.
risk of no viral clearance, 64.0% lower, RR 0.36, p < 0.001, treatment 9 of 27 (33.3%), control 25 of 27 (92.6%), NNT 1.7, 0.5% nasal spray.
risk of no viral clearance, 73.6% lower, RR 0.26, p < 0.001, treatment 29 of 135 (21.5%), control 44 of 54 (81.5%), NNT 1.7, all treatment vs. all control.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Arefin et al., 18 May 2021, Randomized Controlled Trial, Bangladesh, peer-reviewed, 9 authors, trial NCT04549376 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPovidone-Iod..All
Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial
Mostafa Kamal Arefin, S K Nurul Fattah Rumi, A K M Nasir Uddin, Sultana Sahana Banu, Mala Khan, Ahsanul Kaiser, Joybaer Anam Chowdhury, Md. Abdullah Saeed Khan, Mohammad Jahid Hasan
Indian Journal of Otolaryngology and Head & Neck Surgery, doi:10.1007/s12070-021-02616-7
Povidone-iodine (PVP-I) is a time-tested antiseptic agent with excellent virucidal (99.99%) properties. Repurposing it against coronavirus disease-19 (COVID-19) is a relatively newer concept and has been sparsely tested in vivo. The most common route of entry of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is the nasopharynx. Averting colonization of the virus could be one of the best options to reduce the incidence of infection. PVP-I gargle and mouthwash were found to be effective in vitro rapid inactivation against SARS-CoV-2 on a smaller scale (Hassandarvish et al. in BDJ 1-4, 2020, Pelletier et al. in ENTJ 1-5, 2020). However, efficacy in humans is lacking. To assess the virucidal effect of PVP-I against SARS-CoV-2 located in the nasopharynx was the objective of this parallel armed randomized clinical trial. We screened all RT-PCR-confirmed COVID-19 cases aged 18 years and above with symptoms. Written informed consent was obtained before randomization. Nasopharyngeal clearance of SARS-CoV-2 was tested after single time application of PVP-I nasal irrigation (NI) at diluted concentrations of .4%, .5% and .6% and PVP-I nasal spray (NS) at diluted concentrations of .5% and .6%. All groups were compared to the corresponding controls (distilled water). The primary outcome was viral clearance in a repeat RT-PCR (qualitative), and the secondary outcome was the number of adverse events. Final data analysis was performed using the statistical software SPSS (Version 20). A total of 189 confirmed COVID-19 cases were randomized into seven groups: 27 patients in each group. Of all, 159 (84.1%) were male, and 30 (15.9%) were female. We observed a statistically significant proportion of nasopharyngeal clearance with all strengths of PVP-I NI and PVP-I NS compared to the corresponding controls. Additionally, 0.5% NI was significantly better than 0.5% NS for viral clearance (p = 0.018) and had the highest nasopharyngeal clearance among all & Mostafa Kamal Arefin
Author contributions MKA had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conception of the research idea: MKA. Research design: MKA and MJH. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript: All authors. Statistical analysis: ASK, MKA and MJH. Administrative, technical, or material support: AKMNU, MK and SSB. Supervision: MKA, SKNFR, and MJH. The authors read and approved the final manuscript. Funding The trial received research partial grant from BRICM. Data Availability The corresponding author has access to the alltrial information, and the data will be available on reasonable request (contact: or Declarations Conflict of interest The authors declare that they have no competing interests. Ethics approval
Guenezan, Garcia, Strasters, Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19, JAMA-Otolaryngol Neck Surg, doi:10.1001/jamaoto.2020.5490
Hasan, Rumi, Banu, Uddin, Islam et al., Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: a structured summary of a study protocol for an open-label randomized clinical trial, Trials, doi:10.1186/s13063-020-04963-2
Hassandarvish, Tiong, Mohamed, In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice, Br Dent J, doi:10.1038/s41415-020-2402-0
Juszczak, Altman, Hopewell, Schulz, Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement, JAMA, doi:10.1001/jama.2019.3087
Lamas, Dios, Rodrı, Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo Tests Oral Dis, doi:10.1111/odi.13526
Pelletier, Tessema, Frank, Westover, Brown et al., Efficacy of povidone-iodine nasal and oral antiseptic preparations against severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2), Ear Nose Throat J, doi:10.1177/0145561320957237
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop